Skip to content

Debrisoquine

CARDIOVASCULAR SYSTEM

Also known as: debrisoquin, debrisoquin sulfate, isocaramidine

YEAR INTRODUCED approvedATC C02CC04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Debrisoquine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1965. DrugCentral lists 3 molecular targets, including TMPRSS2, MAOB and MAOA.

  • Molecular targets: TMPRSS2, MAOB and MAOA (3 listed in DrugCentral).
  • ATC code: C02CC04 (Guanidine derivatives).
  • Molecular formula: C10H13N3; molecular weight 175.24 g/mol.

Mechanism & targets

Molecular targets (3)

TargetGeneActionActivity
Transmembrane protease serine 2TMPRSS2unknownIC50 4.64
Amine oxidase [flavin-containing] BMAOBunknown—
Amine oxidase [flavin-containing] AMAOAunknown—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1965-01-01YEAR INTRODUCED——

ATC classification

ATC codeTherapeutic hierarchy
C02CC04CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING › Guanidine derivatives

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Debrisoquine is on its molecule page.

Molecular formulaC10H13N3
Molecular weight175.24 g/mol
CAS number1131-64-2
InChIKeyJWPGJSVJDAJRLW-UHFFFAOYSA-N
PubChem CID2966
NC(=N)N1CCC2=CC=CC=C2C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Debrisoquine work?

Its molecular targets in DrugCentral include TMPRSS2, MAOB and MAOA.

When was Debrisoquine first approved?

Debrisoquine was first approved by the YEAR INTRODUCED in 1965.

What is the chemical formula of Debrisoquine?

Debrisoquine has the molecular formula C10H13N3 and a molecular weight of 175.24 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval1965-01-01
AgencyYEAR INTRODUCED
Targets3
Indications0
FormulaC10H13N3
DrugCentral ID788
Interactive profile